TSE:4502Pharmaceuticals
Why Takeda Pharmaceutical (TSE:4502) Is Getting Attention Today
Takeda Pharmaceutical (TSE:4502) is in focus after Japan’s Ministry of Health, Labour and Welfare approved ORZEYFUL, a first in class oral orexin receptor 2 agonist for adult narcolepsy type 1 treatment.
Taken together with the ORZEYFUL approval, Takeda Pharmaceutical’s recent share price has been firm, with a 90 day share price return of 13.27% and a year to date share price return of 17.92%, while the 1 year total shareholder return is 36.18%, suggesting that momentum has been building over...